← catalyst

LLY

5 catalysts · 3 upcoming · 0 awaiting · 2 resolved

Upcoming

[FDA]·Jul 23, 2026
T-86d

Pharmacy Compounding Advisory Committee

▸ analysis · bull/bear · base rate — pro
HIMSLFMDEVOLLYNVO
[PDUFA]·Apr 30, 2026
T-1d

EB613 (ENTX) PDUFA — Osteoporosis

▸ analysis · bull/bear · base rate — pro
ENTXRADSLLYAMGN
[PDUFA]·Apr 30, 2026
T-1d

AXS-05 (dextromethorphan HBr and bupropion HCl) - (ACCORD-2) (AXSM) PDUFA — Agitation in patients with Alzheimer’s disease (AD)

▸ analysis · bull/bear · base rate — pro
AXSMOTSKYLLYBIIB

Resolved

[PDUFA]·Nov 8, 2023
→ FAVORABLE

Tirzepatide (Zepbound) PDUFA — Chronic weight management

▸ analysis · bull/bear · base rate — pro
LLYNVOVKTXAMGNHIMS
[PDUFA]·Jul 6, 2023
→ FAVORABLE

Lecanemab (Leqembi) — Traditional approval for Alzheimer's disease

▸ analysis · bull/bear · base rate — pro
BIIBLLYPRTAACIU